The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of BioXcel Therapeutics Inc (NASDAQ: BTAI) was $0.41 for the day, down -9.66% from the previous closing price of $0.45. In other words, the price has decreased by -$9.66 from its previous closing price. On the day, 1.96 million shares were traded. BTAI stock price reached its highest trading level at $0.4661 during the session, while it also had its lowest trading level at $0.4.
Ratios:
Our analysis of BTAI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.87.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 03 ’24 when Wiley Matthew T. sold 6,272 shares for $0.55 per share. The transaction valued at 3,450 led to the insider holds 19,011 shares of the business.
Rodriguez Javier sold 6,863 shares of BTAI for $3,775 on Oct 03 ’24. The insider now owns 23,770 shares after completing the transaction at $0.55 per share. On Oct 03 ’24, another insider, Yocca Frank, who serves as the Chief Scientific Officer of the company, sold 7,175 shares for $0.55 each. As a result, the insider received 3,946 and left with 28,278 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 21872806 and an Enterprise Value of 68555056. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.83. Its current Enterprise Value per Revenue stands at 28.529 whereas that against EBITDA is -0.657.
Stock Price History:
Over the past 52 weeks, BTAI has reached a high of $4.17, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is -30.05%, while the 200-Day Moving Average is calculated to be -72.89%.
Shares Statistics:
BTAI traded an average of 550.97K shares per day over the past three months and 778450 shares per day over the past ten days. A total of 48.35M shares are outstanding, with a floating share count of 38.54M. Insiders hold about 20.29% of the company’s shares, while institutions hold 6.57% stake in the company. Shares short for BTAI as of 1730332800 were 347081 with a Short Ratio of 1.13, compared to 1727654400 on 516384. Therefore, it implies a Short% of Shares Outstanding of 347081 and a Short% of Float of 1.09.
